Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Aug;28(8):1231-5.
doi: 10.1111/j.1745-7254.2007.00607.x.

Alendronate inhibits cell invasion and MMP-2 secretion in human chondrosarcoma cell line

Te-jen Lai  1 , Sheng-feng Hsu, Te-mao Li, Horng-chaung Hsu, Jaung-geng Lin, Chin-jung Hsu, Ming-chih Chou, Meng-chih Lee, Shun-fa Yang, Yi-chin Fong
Affiliations

Alendronate inhibits cell invasion and MMP-2 secretion in human chondrosarcoma cell line

Te-jen Lai et al. Acta Pharmacol Sin. 2007 Aug.

Abstract

Aim: Chondrosarcoma is a malignant primary bone tumor that responds poorly to both chemotherapy and radiation therapy. The aim of the present study was to investigate the effect of alendronate, a bisphosphonate, on the invasion and migration of human chondrosarcoma cells (JJ012).

Methods: JJ012 cells were treated with alendronate of various concentrations up to 100 micromol/L for a specified period, and then gelatin zymography and matrigel invasion assay was performed to study the effects of alendronate on matrix metalloproteinase (MMP)-2 activity and the invasion ability of JJ012 cells, respectively.

Results: Our data showed that alendronate exerted a dose- and time-dependent inhibitory effect on the invasion and migration of JJ012 cells. Furthermore, gelatin zymography and RT-PCR showed that alendronate treatment decreased the activity and mRNA levels of MMP-2 in a concentration-dependent manner.

Conclusion: Our findings suggest that alendronate may reduce MMP-2 secretion at the transcriptional and translational levels, and inhibit the invasion of chondrosarcoma cell. Therefore, alendronate may be a potential candidate for the systemic therapy of chondrosarcomas, as well as other malignant diseases.

PubMed Disclaimer

Publication types